PMID- 29372560
OWN - NLM
STAT- MEDLINE
DCOM- 20180403
LR  - 20180403
IS  - 1099-0844 (Electronic)
IS  - 0263-6484 (Linking)
VI  - 36
IP  - 2
DP  - 2018 Mar
TI  - Inhibition of the CSF-1 receptor sensitizes ovarian cancer cells to cisplatin.
PG  - 80-87
LID - 10.1002/cbf.3319 [doi]
AB  - Ovarian cancer is one of the most common female malignancies, and cisplatin-based 
      chemotherapy is routinely used in locally advanced ovarian cancer patients. 
      Acquired or de novo cisplatin resistance remains the barrier to patient survival, 
      and the mechanisms of cisplatin resistance are still not well understood. In the 
      current study, we found that colony-stimulating-factor-1 receptor (CSF-1R) was 
      upregulated in cisplatin-resistant SK-OV-3 and CaoV-3 cells. 
      Colony-stimulating-factor-1 receptor knockdown suppressed proliferation and 
      enhanced apoptosis in cisplatin-resistant SK-OV-3 and CaoV-3 cells. However, 
      CSF-1R overexpression had inverse effects. While parental SK-OV-3 and CaoV-3 
      cells were more resistant to cisplatin after CSF-1R overexpression, CSF-1R 
      knockdown in SK-OV-3 and CaoV-3 cells promoted cisplatin sensitivity. 
      Overexpression and knockdown studies also showed that CSF-1R significantly 
      promoted active AKT and ERK1/2 signalling pathways in cisplatin-resistant cells. 
      Furthermore, a combination of cisplatin and CSF-1R inhibitor effectively 
      inhibited tumour growth in xenografts. Taken together, our results provide the 
      first evidence that CSF-1R inhibition can sensitize cisplatin-refractory ovarian 
      cancer cells. This study may help to increase understanding of the molecular 
      mechanisms underlying cisplatin resistance in tumours.
CI  - Copyright (c) 2018 John Wiley & Sons, Ltd.
FAU - Yu, Rong
AU  - Yu R
AD  - Reproductive Center, The First Affiliated Hospital of Wenzhou Medical University, 
      Zhejiang, China.
FAU - Jin, Hao
AU  - Jin H
AD  - Department of Organ Transplantation, The First Affiliated Hospital of Wenzhou 
      Medical University, Zhejiang, China.
FAU - Jin, Congcong
AU  - Jin C
AD  - Reproductive Center, The First Affiliated Hospital of Wenzhou Medical University, 
      Zhejiang, China.
FAU - Huang, Xuefeng
AU  - Huang X
AD  - Reproductive Center, The First Affiliated Hospital of Wenzhou Medical University, 
      Zhejiang, China.
FAU - Lin, Jinju
AU  - Lin J
AD  - Reproductive Center, The First Affiliated Hospital of Wenzhou Medical University, 
      Zhejiang, China.
FAU - Teng, Yili
AU  - Teng Y
AUID- ORCID: 0000-0003-3245-6750
AD  - Reproductive Center, The First Affiliated Hospital of Wenzhou Medical University, 
      Zhejiang, China.
LA  - eng
PT  - Journal Article
DEP - 20180125
PL  - England
TA  - Cell Biochem Funct
JT  - Cell biochemistry and function
JID - 8305874
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, Macrophage Colony-Stimulating Factor)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cisplatin/chemistry/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance, Neoplasm/drug effects
MH  - Drug Screening Assays, Antitumor
MH  - Female
MH  - Humans
MH  - Mice
MH  - Neoplasms, Experimental/drug therapy/metabolism/pathology
MH  - Ovarian Neoplasms/*drug therapy/metabolism/pathology
MH  - Receptor, Macrophage Colony-Stimulating Factor/*antagonists & 
      inhibitors/metabolism
MH  - Structure-Activity Relationship
MH  - Tumor Cells, Cultured
OTO - NOTNLM
OT  - CSF-1R
OT  - cisplatin
OT  - ovarian cancer
OT  - resistance
EDAT- 2018/01/27 06:00
MHDA- 2018/04/04 06:00
CRDT- 2018/01/27 06:00
PHST- 2017/08/08 00:00 [received]
PHST- 2017/10/19 00:00 [revised]
PHST- 2017/12/26 00:00 [accepted]
PHST- 2018/01/27 06:00 [pubmed]
PHST- 2018/04/04 06:00 [medline]
PHST- 2018/01/27 06:00 [entrez]
AID - 10.1002/cbf.3319 [doi]
PST - ppublish
SO  - Cell Biochem Funct. 2018 Mar;36(2):80-87. doi: 10.1002/cbf.3319. Epub 2018 Jan 
      25.